# Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

> **NCT04784455** · PHASE3 · TERMINATED · sponsor: **AKARI Therapeutics** · enrollment: 10 (actual)

## Conditions studied

- Thrombotic Microangiopathies

## Interventions

- **DRUG:** nomacopan (rVA576)

## Key facts

- **NCT ID:** NCT04784455
- **Lead sponsor:** AKARI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-01
- **Primary completion:** 2024-05-15
- **Final completion:** 2024-05-15
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The early termination of this study is a business decision following a portfolio reprioritization plan. The decision is not related to any Efficacy, Safety or Clinical concerns regarding Nomacopan/rVA576
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784455, "Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04784455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*